Sort   by:  
 Page size 
MetabolomicsNiacin restriction with NAMPT-inhibition is synthetic lethal to neuroendocrine carcinoma (Mouse NAMPT targeted therapy)

NAMPT plays a major role in NAD biosynthesis in many cancers and is an attractive potential cancer target. However, factors dictating therapeutic efficacy of NAMPT inhibitors (NAMPTi) are unclear. We report that neuroendocrine phenotypes predict lung and prostate carcinoma vulnerability to NAMPTi...

2023-10-10 | MTBLS7252 | MetaboLights
GenomicsPhage therapy targeted E.coli
Phage therapy targeted E.coli Raw sequence reads
PRJNA1158932 | ENA
ProteomicsWidespread multi-targeted therapy resistance via drug-induced secretome fucosylation
Cancer secretome is a reservoir for aberrant glycosylation. How therapies alter this post translational cancer hallmark and the consequences thereof remain elusive. Here we show that an elevated secretome fucosylation is a pan-cancer signature of both response and resistance to multiple targeted the...
ORGANISM(S): Homo sapiens (Human) 
2023-04-05 | PXD022240 | Pride
N-linked glycosylation Resistance Fucosylation Targeted therapy Secretome 
ProteomicsFFPE tumor samples reveals the influences of NET-1 siRNA nanoparticles and sonodynamic therapy on tetraspanin protein involved in HCC
Hepatocellular carcinoma (HCC) poses a severe threat to human health. The NET-1 protein has been proved to be strongly associated with HCC proliferation and metastasis in our previous study. Here, we established and validated NET-1 siRNA nanoparticles system to conduct targeted gene therapy of HCC x...
ORGANISM(S): Homo sapiens (Human) 
2021-09-09 | PXD020763 | Pride
Ultrasound Proteomics Mass spectrometry Tetraspanin protein Hepatocellular carcinoma Sonodynamic therapy 
GenomicsscRNA-seq of immune cells during targeted therapy-induced tumor regression and targeted therapy tolerant residual melanoma
scRNA-seq of immune cells during targeted therapy-induced tumor regression and targeted therapy tolerant residual melanoma
PRJNA1469541 | ENA
UnknownAdvances in targeted alpha therapy for prostate cancer.
Not available
S-EPMC6927314 | biostudies-literature
GenomicsAcquired resistance to targeted therapy confers cross-resistance to immunotherapy
Acquired resistance to targeted therapy confers cross-resistance to immunotherapy
PRJNA548090 | ENA
TranscriptomicsA molecular signature for MET-targeted therapy
Constitutive MET signaling promotes invasiveness in primary and recurrent GBM; however, current MET-targeting strategies lack of effective biomarkers for selecting suitable patients for treatment. Here, we identified a predictive signature potentially valuable for indicating vulnerability to MET-tar...
ORGANISM(S): Mus musculus 
2016-01-05 | E-GEOD-64667 | biostudies-arrayexpress
UnknownCombination of Immunotherapy With Targeted Therapy: Theory and Practice in Metastatic Melanoma.
Not available
S-EPMC6513976 | biostudies-literature
GenomicsA molecular signature for MET-targeted therapy
A molecular signature for MET-targeted therapy
PRJNA271603 | ENA
Sort   by:  
 Page size